About EyeGate Pharma (NASDAQ:EYEG)
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 treat non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The company was founded in 1998 and is headquartered in Waltham, MA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-9043
Debt
Debt-to-Equity RatioN/A
Current Ratio0.57%
Quick Ratio0.57%
Price-To-Earnings
Trailing P/E Ratio-0.53
Forward P/E Ratio-0.78
P/E GrowthN/A
Sales & Book Value
Annual Sales$410,000.00
Price / Sales23.17
Cash FlowN/A
Price / CashN/A
Book Value($0.11) per share
Price / Book-4.89
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net Margins-2,480.28%
Return on Equity-2,683.87%
Return on Assets-96.01%
Miscellaneous
Employees17
Outstanding Shares17,660,000
EyeGate Pharma (NASDAQ:EYEG) Frequently Asked Questions
What is EyeGate Pharma's stock symbol?
EyeGate Pharma trades on the NASDAQ under the ticker symbol "EYEG."
How were EyeGate Pharma's earnings last quarter?
EyeGate Pharma (NASDAQ:EYEG) released its quarterly earnings data on Friday, March, 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. EyeGate Pharma had a negative return on equity of 2,683.87% and a negative net margin of 2,480.28%. View EyeGate Pharma's Earnings History.
When is EyeGate Pharma's next earnings date?
What price target have analysts set for EYEG?
2 equities research analysts have issued 12 month price targets for EyeGate Pharma's shares. Their forecasts range from $3.00 to $3.00. On average, they expect EyeGate Pharma's stock price to reach $3.00 in the next year. View Analyst Ratings for EyeGate Pharma.
Who are some of EyeGate Pharma's key competitors?
Some companies that are related to EyeGate Pharma include Xenetic Biosciences (XBIO), Ritter Pharmaceuticals (RTTR), Soligenix (SNGX), OHR Pharmaceutical (OHRP), RXi Pharmaceuticals (RXII), Onconova Therapeutics (ONTX), Acura Pharmaceuticals (ACUR), EpiCept (IMNP), Dare Bioscience (DARE), Auris Medical (EARS), Anthera Pharmaceuticals (ANTH), Bioblast Pharma (ORPN), Heat Biologics (HTBX), Apricus Biosciences (APRI), Cotinga Pharmaceuticals (COTQF), Orexigen Therapeutics (OREX), Argos Therapeutics (ARGS) and Rosetta Genomics (ROSG).
Who are EyeGate Pharma's key executives?
EyeGate Pharma's management team includes the folowing people:
- Stephen From, President, Chief Executive Officer & Director
- Sarah M. Romano, Chief Financial & Accounting Officer
- Lisa Brandano, Vice President-Clinical Operations
- Barbara Wirostko, Chief Medical Officer
- Michael P. Manzo, Vice President-Engineering
When did EyeGate Pharma IPO?
(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.
Has EyeGate Pharma been receiving favorable news coverage?
News articles about EYEG stock have trended positive on Saturday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. EyeGate Pharma earned a media sentiment score of 0.29 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 45.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are EyeGate Pharma's major shareholders?
EyeGate Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own EyeGate Pharma stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for EyeGate Pharma.
How do I buy shares of EyeGate Pharma?
Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EyeGate Pharma's stock price today?
One share of EYEG stock can currently be purchased for approximately $0.5380.
How big of a company is EyeGate Pharma?
EyeGate Pharma has a market capitalization of $8.65 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. EyeGate Pharma employs 17 workers across the globe.
How can I contact EyeGate Pharma?
EyeGate Pharma's mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-9043.
MarketBeat Community Rating for EyeGate Pharma (EYEG)
MarketBeat's community ratings are surveys of what our community members think about EyeGate Pharma and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.
EyeGate Pharma (NASDAQ:EYEG) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for EyeGate Pharma in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 457.62%. The high price target for EYEG is $3.00 and the low price target for EYEG is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.00 | $3.00 | $5.00 | $7.3333 |
| Price Target Upside: | 457.62% upside | 424.75% upside | 309.84% upside | 543.27% upside |
EyeGate Pharma (NASDAQ:EYEG) Consensus Price Target History
EyeGate Pharma (NASDAQ:EYEG) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
EyeGate Pharma (NASDAQ:EYEG) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
EyeGate Pharma (NASDAQ EYEG) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 10.47%
EyeGate Pharma (NASDAQ EYEG) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/20/2018 | Armistice Capital Master Fund | Major Shareholder | Buy | 2,534,478 | $0.49 | $1,241,894.22 | |  |
| 4/17/2018 | Armistice Capital Master Fund | Major Shareholder | Buy | 10,479,970 | $0.36 | $3,772,789.20 | | |
| 8/15/2017 | Sarah Romano | CFO | Buy | 10,000 | $1.00 | $10,000.00 | 32,500 | |
| 8/10/2017 | Stephen From | Insider | Buy | 12,500 | $1.03 | $12,875.00 | 272,465 | |
| 3/6/2017 | Morton Goldberg | Director | Sell | 8,919 | $3.00 | $26,757.00 | 9,441 | |
| 9/15/2016 | Stephen From | Insider | Buy | 15,000 | $1.49 | $22,350.00 | 139,965 | |
| 6/15/2016 | Morton Goldberg | Director | Sell | 15,000 | $3.16 | $47,400.00 | 17,277 | |
| 6/10/2016 | Ventech Capital Ii | Major Shareholder | Sell | 28,600 | $3.04 | $86,944.00 | 1,608,973 | |
| 6/8/2016 | Ventech Capital Ii | Major Shareholder | Sell | 29,400 | $3.25 | $95,550.00 | 1,641,540 | |
| 6/7/2016 | Morton Goldberg | Director | Sell | 10,939 | $3.31 | $36,208.09 | 43,216 | |
| 2/19/2015 | (Innoven Partenaires S.A. Ipsa | Major Shareholder | Buy | 366,667 | $6.00 | $2,200,002.00 | | |
| 2/19/2015 | Paul G Chaney | Director | Buy | 8,333 | $6.00 | $49,998.00 | | |
(Data available from 1/1/2013 forward)
EyeGate Pharma (NASDAQ EYEG) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insider Buying: EyeGate Pharma (EYEG) Major Shareholder Purchases 2,534,478 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM |
 | Form 4 EYEGATE PHARMACEUTICALS For: Apr 17 Filed by: FROM STEPHEN
www.streetinsider.com - April 20 at 8:24 AM |
| EyeGate Pharma (EYEG) Major Shareholder Armistice Capital Master Fund Buys 10,479,970 Shares
www.americanbankingnews.com - April 18 at 10:21 AM |
 | Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data
seekingalpha.com - April 16 at 8:16 AM |
| EyeGate Pharma (EYEG) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 14 at 10:05 AM |
 | Mid-Afternoon Market Update: Skyline Rises After Q3 Results; EyeGate Pharmaceuticals Shares Plunge
feeds.benzinga.com - April 13 at 3:36 PM |
| EyeGate Pharma to Post Q2 2018 Earnings of ($0.21) Per Share, Zacks Investment Research Forecasts (EYEG)
www.americanbankingnews.com - April 13 at 8:47 AM |
| Eyegate Pharma (EYEG) Announces $11.25 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - April 13 at 8:19 AM |
| EyeGate Pharma prices $11.25M equity offering; shares down 24% premarket
seekingalpha.com - April 13 at 8:19 AM |
| Eyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens Technology
www.streetinsider.com - April 12 at 5:38 PM |
| Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain
www.benzinga.com - April 11 at 5:31 PM |
| EyeGate nabs U.S. patent covering iontophoretic contact lens; shares up 29%
seekingalpha.com - April 11 at 5:31 PM |
 | EyeGate Issued New Patent for Iontophoretic Contact Lens Technology
finance.yahoo.com - April 11 at 5:31 PM |
| Eyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage Gel
www.streetinsider.com - April 10 at 8:27 AM |
| Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
seekingalpha.com - April 10 at 8:27 AM |
| EyeGate sees Q3 start for second pilot study of lead candidate EyeGate OBG; shares slip 6% premarket
seekingalpha.com - April 9 at 5:22 PM |
 | BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
www.reuters.com - April 6 at 5:41 PM |
| EyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarket
seekingalpha.com - April 6 at 5:41 PM |
| Head-To-Head Contrast: EyeGate Pharma (EYEG) versus Regulus Therapeutics (RGLS)
www.americanbankingnews.com - April 2 at 1:16 PM |
| EyeGate Pharma (EYEG) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM |
| Eyegate Pharmaceuticals (EYEG) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM |
| BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
www.reuters.com - March 23 at 5:42 PM |
| Eyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 18 at 9:22 PM |
 | EyeGate Pharma To Participate At The 30TH Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 10 at 8:22 AM |
| EyeGate Pharma To Participate At The 30TH Annual ROTH Conference
finance.yahoo.com - March 9 at 6:50 PM |
 | EyeGate Pharma Submits Investigational Device Exemption ... - Nasdaq
www.nasdaq.com - March 9 at 8:20 AM |
| Analysts Set Expectations for Eyegate Pharmaceuticals Inc's Q1 2018 Earnings (EYEG)
www.americanbankingnews.com - March 9 at 7:54 AM |
| EyeGate Pharma Submits Investigational Device Exemption ... - GlobeNewswire (press release)
globenewswire.com - March 8 at 6:44 PM |
| Eyegate Pharma (EYEG) Submits Investigational Device Exemption ... - StreetInsider.com
www.streetinsider.com - March 8 at 6:44 PM |
| EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?
finance.yahoo.com - March 8 at 6:44 PM |
| FY2020 Earnings Estimate for Eyegate Pharmaceuticals Inc Issued By Zacks Investment Research (EYEG)
www.americanbankingnews.com - March 8 at 2:32 PM |
| HC Wainwright Analysts Give Eyegate Pharmaceuticals (EYEG) a $3.00 Price Target
www.americanbankingnews.com - March 5 at 2:58 PM |
| EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:16 AM |
| EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 2 at 6:10 PM |
| FY2019 EPS Estimates for Eyegate Pharmaceuticals Inc (EYEG) Lowered by Zacks Investment Research
www.americanbankingnews.com - February 23 at 3:52 PM |
| EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint
finance.yahoo.com - February 22 at 5:37 PM |
| Eyegate Pharmaceuticals (EYEG) to Release Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:20 AM |
| Head-To-Head Review: Eyegate Pharmaceuticals (EYEG) versus Lannett (LCI)
www.americanbankingnews.com - February 12 at 3:36 AM |
| EyeGate to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:34 AM |
| Eyegate Pharmaceuticals (EYEG) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - February 7 at 12:40 AM |
| Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher
www.benzinga.com - February 5 at 3:41 PM |
| What Spooked Eyegate Pharmaceuticals Inc Investors Today
finance.yahoo.com - February 5 at 3:41 PM |
| What Spooked Eyegate Pharmaceuticals Inc Investors Today
finance.yahoo.com - February 5 at 3:41 PM |
| Eyegate Pharma (EYEG) Reports Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
www.streetinsider.com - February 5 at 9:34 AM |
| EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
finance.yahoo.com - February 5 at 9:34 AM |
| Reviewing Eyegate Pharmaceuticals (EYEG) & Lannett (LCI)
www.americanbankingnews.com - February 1 at 11:33 AM |
| Eyegate Pharmaceuticals Inc (EYEG) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 26 at 7:12 PM |
| Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?
finance.yahoo.com - January 20 at 9:29 AM |
| Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position
www.streetinsider.com - January 4 at 5:25 PM |
| Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position - StreetInsider.com
www.streetinsider.com - January 4 at 9:23 AM |
EyeGate Pharma (NASDAQ:EYEG) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
EyeGate Pharma (NASDAQ EYEG) Stock Chart for Saturday, April, 21, 2018
Loading chart…
